Lanreotide Acetate Injection
Product Images NDC 70121-2517

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Lanreotide Acetate (NDC 70121-2517). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Lanreotide Injection Matoda 1)

Chemical structure of lanreotide acetate, showing a cyclic peptide with disulfide bridges and its amino acid sequence elements, consistent with the active ingredient lanreotide acetate.*

FDA Label Image

1 (Lanreotide Injection Matoda 10)

An instructional illustration showing hands being washed under running water from a faucet, with a visible soap dispenser in the background. The image emphasizes proper handwashing technique.*

FDA Label Image

Ifu7th (Lanreotide Injection Matoda 11)

An instructional illustration showing hands peeling back a label from a pre-filled syringe and a labeled diagram of the syringe assembly. The syringe contains Lanreotide Acetate injection and includes parts labeled: needle cap, pre-filled syringe body, expiration date and dose label, and tray. It demonstrates handling and identification of packaging for a subcutaneous injection.*

FDA Label Image

Ifu8th (Lanreotide Injection Matoda 12)

An illustration showing the internal mechanism of the LANREOTIDE ACETATE subcutaneous injection device, highlighting the syringe and dosing components in a cross-sectional view. The image displays detailed parts of the injection system used for administering the 120 mg/.5mL dosage by Amneal Pharmaceuticals LLC.*

FDA Label Image

1 (Lanreotide Injection Matoda 13)

An instructional diagram showing acceptable subcutaneous injection sites on the outer upper buttocks, labeled "L" for left and "R" for right, each marked with "OK" in white circles, illustrating proper injection locations for LANREOTIDE ACETATE 120 mg/.5 mL injection.*

FDA Label Image

1 (Lanreotide Injection Matoda 14)

An illustration showing a person's lower back and buttocks with a hand holding a cloth, demonstrating proper cleaning of the injection site for subcutaneous administration.*

FDA Label Image

1 (Lanreotide Injection Matoda 15)

Instructional illustration showing hands opening a sealed tray to remove a prefilled syringe of lanreotide acetate injection for subcutaneous administration.*

FDA Label Image

1 (Lanreotide Injection Matoda 16)

An instructional illustration showing the removal of a gray protective cap and a transparent needle cover from a prefilled syringe. The hands demonstrate a pulling motion away from the syringe to separate the components before injection.*

FDA Label Image

1 (Lanreotide Injection Matoda 17)

Illustration showing a right hand holding a syringe for subcutaneous injection, with the needle pointing left. The syringe appears to be pre-filled and is held with the thumb on the plunger and the fingers wrapped around the barrel.*

FDA Label Image

1 (Lanreotide Injection Matoda 18)

An instructional illustration showing proper and improper injection sites on the buttocks for subcutaneous administration. The top section depicts a hand giving an injection to the upper outer quadrant of the buttock labeled 'OK,' indicating the correct site. The bottom section shows an injection in the center of the buttock with a large black X over it, indicating an incorrect site.*

FDA Label Image

1 (Lanreotide Injection Matoda 19)

An instructional diagram showing the administration of a subcutaneous injection into the buttock area using a syringe with an attached needle. The image focuses on hand positioning and injection site for the medication.*

FDA Label Image

1 (Lanreotide Injection Matoda 2)

A Kaplan-Meier survival curve showing progression-free survival probability (%) over time in months for Lanreotide injection compared to placebo. The graph includes subject numbers at risk for each treatment group at various time points up to 24 months. Statistical values provided are hazard ratio 0.47, 95% confidence interval 0.30 to 0.73, and p-value less than 0.001.*

FDA Label Image

Ifu9th (Lanreotide Injection Matoda 20)

An instructional illustration for LANREOTIDE ACETATE 120 mg subcutaneous injection showing a hand holding a syringe with an arrow indicating the plunger should be pushed, and a clock indicating to wait 20 seconds, likely to ensure complete administration of the injection.*

FDA Label Image

1 (Lanreotide Injection Matoda 21)

An instructional illustration showing a hand holding a prefilled syringe of LANREOTIDE ACETATE 120 mg/0.5 mL injection for subcutaneous use. The image depicts the removal of the needle cap by pulling it straight off, indicated by a directional arrow.*

FDA Label Image

1 (Lanreotide Injection Matoda 22)

An instructional illustration showing three sequential steps on how to prepare the Lanreotide Acetate 120 mg injection syringe for use. The images depict hands holding the syringe and manipulating the plunger, demonstrating the process of priming or preparing the subcutaneous injection device.*

FDA Label Image

1 (Lanreotide Injection Matoda 23)

Illustration showing the preparation of the upper outer quadrant of the buttock with a hand holding a cloth, likely depicting skin cleaning before a subcutaneous injection.*

FDA Label Image

1 (Lanreotide Injection Matoda 24)

An instructional illustration showing a hand holding a prefilled syringe poised to insert it into a device, likely a mixing or activation cassette, against a light blue background. The image visually guides the preparation or use of an injection product.*

FDA Label Image

1 (Lanreotide Injection Matoda 25)

An instructional illustration showing a person washing their hands with soap and water under a running faucet. A bottle of liquid soap is visible on the sink, and foam covers the hands during the washing process.*

FDA Label Image

1 (Lanreotide Injection Matoda 26)

Label for Lanreotide Injection 120 mg/0.5 mL, a subcutaneous injection for single-dose use. Distributed by Amneal Pharmaceuticals LLC, made in India. The label includes dosing instructions, batch coding area, and a barcode.*

FDA Label Image

1 (Lanreotide Injection Matoda 27)

Label for Lanreotide Injection 120 mg/0.5 mL, a subcutaneous injection by Amneal Pharmaceuticals LLC. The label states it is for single-dose use, includes storage instructions to refrigerate, and notes it is manufactured by Amneal Pharmaceuticals Pvt. Ltd, India. It includes cautions and a barcode at the bottom.*

FDA Label Image

1 (Lanreotide Injection Matoda 28)

The packaging label for Lanreotide Injection 120 mg/0.5 mL, a subcutaneous human prescription drug by Amneal Pharmaceuticals LLC. The box is designed for a single-dose pre-filled syringe and includes storage instructions, barcode, and the labeler information.*

FDA Label Image

Ifu1st (Lanreotide Injection Matoda 3)

An illustration showing a box of Lanreotide Injection 120 mg/0.5 mL by Amneal Pharmaceuticals LLC. Annotations indicate the box is undamaged, the expiration date is valid, and the dose shown is the prescribed 120 mg.*

FDA Label Image

Ifu2nd (Lanreotide Injection Matoda 4)

LANREOTIDE ACETATE 120 mg/0.5 mL subcutaneous injection packaging displayed inside a refrigerator shelf. The box is primarily white with blue accents and shows the product name and some regulatory and manufacturing details. It is labeled as an Amneal Pharmaceuticals LLC product. A milk carton is visible beside the box.*

FDA Label Image

1 (Lanreotide Injection Matoda 5)

An illustration of a calendar page displaying the date October 29. The calendar page includes time markings from 9 to 2 below the date. The image appears to be a simple, stylized graphic without additional text or labeling.*

FDA Label Image

Ifu3rd (Lanreotide Injection Matoda 6)

Lanreotide Injection 120 mg/.5 mL subcutaneous injection by Amneal Pharmaceuticals LLC. The label shows a single-dose subcutaneous injection with storage instructions advising refrigeration. The packaging is predominantly white with blue accents and includes lot and expiration date fields.*

FDA Label Image

Ifuth (Lanreotide Injection Matoda 7)

Packaging label for LANREOTIDE ACETATE Injection 120 mg/0.5 mL by Amneal Pharmaceuticals LLC. The label features printed drug information and a barcode on a white background. The product is a subcutaneous injection.*

FDA Label Image

Ifuth (Lanreotide Injection Matoda 8)

An instructional illustration showing a person lying down on their side with the word 'OK' in a circle near the hip area. The text below reads 'Laying down,' indicating a suggested body position for administering a subcutaneous injection.*

FDA Label Image

Ifu6th (Lanreotide Injection Matoda 9)

Illustration showing the back view of a standing person with recommended injection sites labeled "OK" on the outer upper areas of both buttocks, indicating appropriate subcutaneous injection locations for LANREOTIDE ACETATE.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.